ROCKVILLE, MD and SHENZHEN, CHINA – [Feb 2, 2026] — HighTide Therapeutics, Inc. (2511.HK), a biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic metabolic diseases with significant unmet medical needs, announced today the appointment of Dr. Filip Surmont as Chief Medical Officer. Dr. Surmont will oversee the company’s global medical strategy, clinical development, and medical affairs, accelerating the clinical progress and value enhancement of HighTide’s core pipeline in the field of cardiovascular-kidney-metabolic (CKM) diseases.
Dr. Filip Surmont brings over 30 years of extensive experience in the healthcare and pharmaceutical industries, including 18 years in leadership positions at multinational pharmaceutical companies and 16 years of clinical practice. A globally recognized leader in the field of cardiovascular, metabolic, and renal diseases, he previously held senior medical leadership positions at Wyeth, Pfizer, and AstraZeneca. He has led medical affairs across diverse regions—including emerging markets, Latin America, Europe, the U.S., and China—successfully building high-performance teams and driving large-scale, guideline-level clinical practice transformations within complex global healthcare systems.
Throughout his distinguished career, Dr. Filip Surmont has contributed to the success of dapagliflozin as a blockbuster medication; led the “ACT on HF” project in China, enabling 200,000 heart failure patients to benefit from guideline-recommended standard of care; pioneered the Anti-Inflammatory Reliever (AIR) therapy strategy for asthma, impacting approximately 50 million patients worldwide and driving updates to international treatment guidelines. As a distinguished scientist, Dr. Filip Surmont has authored numerous peer-reviewed articles in elite medical journals, including The Lancet Diabetes & Endocrinology and Journal of the American College of Cardiology. In his early professional career, Dr. Filip Surmont has provided medical services for Olympic-level athletes. He holds an M.D. and a Master’s degree in Sports Medicine from Ghent University, Belgium.
“We warmly welcome Dr. Filip Surmont to HighTide Therapeutics as our Chief Medical Officer,” said Dr. Liping Liu, Founder, Chairman, and CEO of HighTide Therapeutics. “He brings vast global experience, exceptional medical leadership, and a proven track record of success in the field of cardiovascular, metabolic, and renal diseases. We believe his appointment will further strengthen our medical and clinical development capabilities, bolstering the global development and partnerships for our core CKM pipeline and providing powerful momentum for the company’s next phase of growth.”
Dr. Filip Surmont, Chief Medical Officer of HighTide Therapeutics, stated: “I am honored to join HighTide. The company’s R&D strategy and pipeline in metabolic diseases—particularly the clinical potential of its core products in CKM—align perfectly with the significant unmet medical needs in global chronic metabolic care. I look forward to working closely with the team to drive the value transformation of our innovative therapies and bring new treatment options to CKM patients worldwide.”
About HighTide Therapeutics
HighTide Therapeutics, Inc. (2511.HK) is a biopharmaceutical company dedicated to developing multifunctional, multi-targeted therapies for chronic metabolic diseases, with a strategic emphasis to address the residual risks of cardiovascular-kidney-metabolic (CKM) syndrome. The company focuses on delivering breakthrough treatments that generate comprehensive, multi-organ benefits for patients worldwide. HighTide has built an innovative, globally integrated pipeline with 100% proprietary intellectual property and has advanced multiple clinical programs across multiple indications in various countries and regions. The company’s lead asset, HTD1801, has received two Fast Track designations and one Orphan Drug designation from the US Food and Drug Administration (FDA), and has been selected for China’s “Major New Drug Innovation” in the National Science and Technology Major Project.
For more information, please visit: www.hightidetx.com or contact: pr@hightidetx.com